United Therapeutics counsel sells 8,300 shares

Q: How many UTHR shares did Paul A. Mahon sell, and at what prices?

Paul A. Mahon sold 8,300 United Therapeutics common shares on October 15, 2026, in six transactions at reported weighted-average prices from $541.6421 to $546.5608 per share. The sales were made under a pre-arranged 10b5-1 plan entered into August 11, 2025.

Q: How many UTHR stock options did Paul A. Mahon exercise, and how many remained?

He exercised options for 8,300 common shares at an exercise price of $146.03 per share on October 15, 2026. His reported position following the exercise was 30,940 stock options.

The EVP & General Counsel's exercise and sales were made under a pre-arranged 10b5-1 plan entered into August 11, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

United Therapeutics Corp. (UTHR) EVP & General Counsel Paul A. Mahon exercised options for 8,300 common shares on October 15, 2026, at an exercise price of $146.03 per share, then sold the 8,300 shares in six transactions at reported weighted-average prices from $541.6421 to $546.5608 per share. The exercise and sales were made under a pre-arranged 10b5-1 plan entered into August 11, 2025. After the exercise, his reported position was 30,940 stock options.

Insider Trade Summary 10b5-1

Exercise and Sale: 8,300 shares ($3.31M approx. pre-tax spread)

Exercise and Sale 8 txns

Insider MAHON PAUL A

Role EVP & GENERAL COUNSEL

Sold 8,300 shs ($4.52M)

Approx. gross sale proceeds $4.52M

Approx. exercise cost $1.21M

Approx. pre-tax spread $3.31M

Type	Security	Shares	Price	Value
Exercise	Stock Option ^F1	8,300	$0.00	$0.00
Exercise	Common Stock ^F1	8,300	$146.03	$1.21M
Sale	Common Stock ^{F1, F2}	268	$541.6421	$145K
Sale	Common Stock ^{F1, F3}	1,924	$542.4914	$1.04M
Sale	Common Stock ^{F1, F4}	1,983	$543.5556	$1.08M
Sale	Common Stock ^{F1, F5}	791	$544.8485	$431K
Sale	Common Stock ^{F1, F6}	2,615	$545.6873	$1.43M
Sale	Common Stock ^{F1, F7}	719	$546.5608	$393K

Holdings After Transaction: Stock Option — 30,940 contracts (Direct); Common Stock — 45,172 shares (Direct)

Footnotes (7)

F1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
F2. This transaction was executed in multiple trades at prices ranging from $541.015 to $541.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3. This transaction was executed in multiple trades at prices ranging from $542.035 to $542.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4. This transaction was executed in multiple trades at prices ranging from $543.155 to $544.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5. This transaction was executed in multiple trades at prices ranging from $544.22 to $545.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6. This transaction was executed in multiple trades at prices ranging from $545.23 to $546.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7. This transaction was executed in multiple trades at prices ranging from $546.27 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Key Figures

Options exercised: 8,300 shares Exercise price: $146.03 per share Shares sold: 8,300 shares +2 more

5 metrics

Options exercised 8,300 shares October 15, 2026

Exercise price $146.03 per share Options exercised October 15, 2026

Shares sold 8,300 shares Six transactions on October 15, 2026

Reported weighted-average sale prices $541.6421 to $546.5608 per share Six reported sales on October 15, 2026

Stock options following exercise 30,940 stock options Following the October 15, 2026 exercise

Key Terms

pre-arranged 10b5-1 plan, weighted average price, exercise price

3 terms

pre-arranged 10b5-1 plan regulatory

"pursuant to a pre-arranged 10b5-1 plan"

weighted average price financial

"reflects the weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

exercise price financial

"at an exercise price of $146.03 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many UTHR shares did Paul A. Mahon sell, and at what prices?

Paul A. Mahon sold 8,300 United Therapeutics common shares on October 15, 2026, in six transactions at reported weighted-average prices from $541.6421 to $546.5608 per share. The sales were made under a pre-arranged 10b5-1 plan entered into August 11, 2025.

How many UTHR stock options did Paul A. Mahon exercise, and how many remained?

He exercised options for 8,300 common shares at an exercise price of $146.03 per share on October 15, 2026. His reported position following the exercise was 30,940 stock options.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/16/2026 - 04:34 PM EDT Accepted by SEC EDGAR 10/16/2026 - 04:34 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAHON PAUL A

(Last)

(First)

(Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING

MARYLAND

20910

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP & GENERAL COUNSEL

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/15/2026		M⁽¹⁾		8,300	A	$146.03	53,472	D
Common Stock	10/15/2026		S⁽¹⁾		268	D	$541.6421⁽²⁾	53,204	D
Common Stock	10/15/2026		S⁽¹⁾		1,924	D	$542.4914⁽³⁾	51,280	D
Common Stock	10/15/2026		S⁽¹⁾		1,983	D	$543.5556⁽⁴⁾	49,297	D
Common Stock	10/15/2026		S⁽¹⁾		791	D	$544.8485⁽⁵⁾	48,506	D
Common Stock	10/15/2026		S⁽¹⁾		2,615	D	$545.6873⁽⁶⁾	45,891	D
Common Stock	10/15/2026		S⁽¹⁾		719	D	$546.5608⁽⁷⁾	45,172	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option	$146.03	10/15/2026		M⁽¹⁾			8,300	03/15/2020	03/15/2027	Common Stock	8,300	$0.00	30,940	D

Explanation of Responses:

1. This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.

2. This transaction was executed in multiple trades at prices ranging from $541.015 to $541.97. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

3. This transaction was executed in multiple trades at prices ranging from $542.035 to $542.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $543.155 to $544.07. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $544.22 to $545.17. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. This transaction was executed in multiple trades at prices ranging from $545.23 to $546.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

7. This transaction was executed in multiple trades at prices ranging from $546.27 to $547.06. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR